Search for: rheumatoid arthritis methotrexate autoimmune disease biomarker gene expression GWAS HLA genes non-HLA genes
| ID | PMID | Title | PublicationDate | abstract |
|---|---|---|---|---|
| 6992265 | Occurrence of deficient monocyte yeast cell phagocytosis in presence of rheumatic sera. | 1980 | Monocyte yeast cell phagocytosis was studied in 164 rheumatic sera. The results showed that the phagocytic activity (PA) was low in 51 per cent of SLE-sera, in 12 per cent of other connective tissue disease (CTD)-sera, in 16 percent of RA-sera but in none of 30 sera from patients with other chronic arthritides. Low PA was associated with cryoglobulinaemia and subnormal C1q, C4 and C3 in the SLE-group and with subnormal C4 and signs of extra-articular disease in the RA-group. In the CTD-group, low PA was only found in 4 cases of SLE-like syndromes, all having evidence of vasculitis. The findings suggest that low phagocytic activity in presence of rheumatic sera may be related to clinical syndromes with circulating immune complexes and/or hypocomplementaemia, most often SLE. | |
| 7358755 | Perforation of the femoral shaft during total hip replacement. | 1980 Mar | Perforation of the femoral shaft by the prosthetic stem as a complication of total hip replacement is not well described in the literature. We studied twelve patients with this complication in order to define the predisposing factors, optimum management, and long-term outcome. Each patient was found to have one or more of the following factors: female sex, osteoporosis, previous fracture, or previous surgery. Once the complication was recognized, management consisted of protected weight-bearing for six weeks. All but two of the patients were asymptomatic after an average follow-up of five years. Judging from the long-term roetgenographic follow-up, penetration of the femoral shaft does not appear to seriously compromise the fixation of the femoral component. | |
| 7018410 | Immunoprotein deposition in synovial tissue in Reiter's syndrome. | 1981 Jun | The aetiology of Reiter's syndrome (RS) is unknown. In order to evaluate the role of immunological mechanisms in this disease we performed synovial biopsies on 12 patients with RS looking for deposition of immunoglobulins and complement components in synovial tissue. By immunofluorescent techniques 11 synovia were found to have immunoprotein deposition. IgM deposition was found around vessels in 8 synovia and in the interstitial tissue in 4. C3 was present perivascularly in 11 cases; in 4 of those there was also staining in the interstitial tissue. No immunoproteins were found in infiltrating or synovial lining cells. The finding of immunoproteins in the synovium of the majority of patients with RS suggests that immunological mechanisms are involved in the pathogenesis of this disease. | |
| 6350855 | Comparative pathology of connective tissue diseases. | 1983 | Selected examples of animal models for human connective tissue diseases are reviewed, with emphasis on those which can be verified by genetic, immunologic, and biochemical studies. Desnick et al. have stated that the study of animal models in inborn errors of metabolism will "have a dramatic impact on the future development and evaluation of effective therapies for a variety of human enzyme diseases." It is hoped that these discussions, including comments on the importance of animal models for specific human diseases of the connective tissue, will yield significant benefits in human health. | |
| 114638 | Distribution of gold in blood following administration of auranofin (SK&F D-39162). | 1979 | After oral administration of auranofin (SK&F D-39162), a new antiarthritic gold compound, to rats, dogs and humans, a major portion (approximately 50%) of the blood gold content was found to be associated with cellular components. This property is in marked contrast to that reported for gold sodium thiomalate and represents another of the many physical, chemical and pharmacological differences between these therapeutic gold compounds. Although the clinical significance of this property is not presently known, it is recommended that pharmacokinetic studies involving auranofin include the assessment of both blood and serum gold levels. | |
| 46694 | The identification of lupus erythematosus cells. A comparison of supravital fluorochromati | 1975 Feb | A comparison of standard Wright's stained lupus erythematosus preparations and an acridine orange fluorochromatic method was conducted using 354 consecutive lupus erythematosus preparations involving 264 patients. The results of this comparison and a discussion of the fluorochromatic procedure are presented. | |
| 6442711 | A double-blind study comparing sodium aurothiomalate and auranofin in patients with rheuma | 1984 | Auranofin, an orally active gold preparation, was compared with sodium aurothiomalate in a double-blind trial in patients with rheumatoid arthritis fulfilling the ARA criteria, who had been stabilized on sodium aurothiomalate for at least six months. Twenty-four patients have so far been entered in the trial, of whom fourteen have been randomly allocated to receive auranofin and ten to receive sodium aurothiomalate. After initial stabilization, patients receive either auranofin 6 mg daily and placebo injection, or sodium aurothiomalate 50 mg monthly and placebo tablets. Five patients have completed one year on auranofin. The remaining nine patients were withdrawn because of loss of efficacy (two), side-effects, (five), loss of efficacy and side-effects (one) and default (one). Four patients have completed one year's treatment with sodium aurothiomalate. Of the remaining six patients, two were withdrawn because of side-effects, three because of poor disease control and one because of side-effects and poor disease control. Diarrhoea occurred in eight patients receiving auranofin. Rashes occurred in both groups but otherwise there were no serious side-effects. The efficacy of both drugs appeared similar, there being no significant differences in morning stiffness, fatiguability, visual analogue pain score, grip strength and articular index. There were also no significant differences in laboratory parameters of efficacy. Auranofin appears to control disease activity in rheumatoid arthritis but diarrhoea is a frequent side-effect. | |
| 6740135 | In vitro synthesis of IgM and IgM rheumatoid factor in seronegative arthritides. | 1984 | In vitro patterns of IgM and IgM rheumatoid factor (RF) synthesis exhibited by peripheral blood B cells (MNL) obtained from healthy individuals as well as patients with seropositive and seronegative rheumatoid arthritis (RA) have been previously examined. The present study was performed in a group of patients with non-rheumatoid seronegative arthritis (SNA) in order to compare patterns of in vitro IgM and IgM RF synthesis to that previously observed with seropositive and seronegative RA. Eighteen patients with SNA (4 ankylosing spondylitis, 10 psoriatic arthritis, and 4 unclassified variant disease) were studied as well as 18 healthy adult controls. Spontaneous release of IgM RF by MNL was not observed in SNA or controls. In contrast, IgM RF was detected in pokeweed mitogen (PWM)-stimulated MNL culture supernatants from 9/18 SNA (mean +/- SD = 17.0 +/- 9.9 ng/10(6) cells), and 10/18 normal controls (16.7 +/- 9.9 ng). Synthesis of IgM by PWM-stimulated MNL from SNA (2062 +/- 1200 ng) was significantly less than observed with MNL from controls (4093 +/- 1896 ng) (P less than 0.001). There were no differences among the various SNA subsets with regards to the levels of IgM and IgM RF produced either spontaneously or after PWM stimulation. IgM RF constituted a small fraction of the total IgM in SNA and normals (0.9% and 0.5%, respectively). This is clearly distinct from seropositive RA in which we have previously established that IgM RF constitutes a substantial fraction of the total IgM (10.7%) (P less than 0.01). IgM and IgM RF production did not appear to be significantly influenced by immunosuppressive medication.(ABSTRACT TRUNCATED AT 250 WORDS) | |
| 6692605 | Factors influencing the incidence and outcome of infection following total joint arthropla | 1984 Jan | During a ten-year period, 4240 total hip, knee, and elbow arthroplasties were performed. The overall infection rate was 1.25%. Certain groups were identified as being at higher risk of infection following total joint arthroplasty: rheumatoid arthritics were at 2.6 times greater risk than osteoarthritics; patients undergoing total hip arthroplasty as a revision of a previous operation were eight times more likely to have infection than those undergoing a primary operation; and patients with metal-to-metal hinged knee prostheses, when compared with patients with metal-to-plastic knee prostheses, were 20 times more likely to have infection. The majority of infections could be attributed either to perioperative problems or late bacterial seeding from a distant site. Although most infections occurred by two years after operation, late infections, particularly in rheumatoid patients via the hematogenous route, occurred as long as nine years after operation. There was no correlation between the Gram's-staining characteristics of the pathogen and the outcome of the infected joint. Gram-negative organisms were frequent in the perioperative period and reflected either nosocomial infection or the ineffectiveness of the prophylactic antibiotic regimen used in inhibiting gram-negative pathogens. The major factors that influenced the outcome of the infected joint included the interval from the initial surgery to recognition of infection, the delay in institution of appropriate treatment, the particular joint that was infected, the integrity of the bone-cement interface, the type of prosthesis used, and the host susceptibility. Identification of high-risk groups and the recognition that patients with joint implants are at risk of infection at any time in the postoperative period may lead to a lowered infection rate in the future. | |
| 6705011 | Once-daily treatment of rheumatoid arthritis with choline magnesium trisalicylate. | 1984 | A pilot study evaluated once-daily treatment of rheumatoid arthritis with choline magnesium trisalicylate (CMT) in patients diagnosed as having classical or definite rheumatoid arthritis, with morning stiffness as a major complaint. Twenty patients were selected who, in an earlier phase of the study, had found twice-daily treatment with CMT effective and tolerable. Efficacy was evaluated in 15 of these patients and safety was evaluated in all 20. Comparisons were made with the twice-daily regimen and with previous nonsteroidal anti-inflammatory drug (NSAID) therapy. Changes in clinical indicators (numbers of painful and swollen joints and the duration of morning stiffness) showed that once-daily treatment with CMT was as effective as twice-daily treatment with CMT or as treatment with other prior NSAIDs in controlling signs and symptoms of rheumatoid arthritis. Side effects in both the twice-daily and the once-daily treatment regimens were similar in incidence and nature. | |
| 6497464 | Antibodies to peptidoglycan in patients with spondylarthritis: a clue to disease aetiology | 1984 Oct | Although the aetiology of the spondylarthritic diseases, ankylosing spondylitis and Reiter's syndrome, is obscure, a clue to the pathogenesis might be an animal model, adjuvant arthritis. Rats with this disease develop a spectrum of pathology with marked similarity to the spondylarthritides. Since peptidoglycan, a major cell wall component of most bacteria is causally implicated in adjuvant arthritis, we sought evidence that peptidoglycan exposure accompanies both Reiter's syndrome and ankylosing spondylitis. Antibodies to the D-Ala-D-Ala moiety of peptidoglycan were measured by a sensitive and specific ELISA. Antibodies were elevated significantly in patients with ankylosing spondylitis or Reiter's syndrome, but not in patients with rheumatoid arthritis or degenerative joint disease in comparison with normal controls. The findings should be considered preliminary, since only a minority of patients had increased antibody titres. However, the findings are compatible with the hypothesis that peptidoglycan is causally related to spondylarthritis. Antibodies to other moieties in the peptidoglycan molecule might be a more sensitive test for significant exposure. | |
| 6328695 | HLA-DR antigens and the antibody response against Epstein-Barr virus. | 1984 Mar | Antibodies against Epstein-Barr virus (EBV) antigens, i.e. the viral capsid antigen (VCA) and the Epstein-Barr nuclear antigen (EBNA), were determined in two independent populations with known HLA-DR phenotypes. The first population consisted of 151 patients with rheumatoid arthritis; the second one of 88 healthy parents of leukemic children. Although the group of patients with rheumatoid arthritis differed significantly in the frequency of 4 DR antigens from the second group, both groups had the same correlation between HLA-DR antigens and the antibody response to EBV antigens. There was a significant correlation between HLA-DR1 and reduced titers of antibodies to VCA, whereas the persons with only one identifiable DR antigen had higher anti-VCA titers. The persons with HLA-DR5 had significantly higher anti-EBNA titers than those without DR5. | |
| 3886218 | Features of synovial membrane identified with monoclonal antibodies. | 1985 Mar | As part of a study of the characteristics of the synovial membrane which make it susceptible to inflammatory reactions, we tested a number of monoclonal antibodies (MoAb) which revealed novel features of the synovium using tissue from rheumatoid, osteoarthritic and traumatized (mechanically deranged) joints. In a previous study we detected macrophages (Mph) lining the synovial membrane by means of Mph specific and HLA-DR specific MoAb. These may account for the type A synoviocytes. Type B synoviocytes are thought to be fibroblastic and we used an anti-Thy 1 MoAb to identify these cells. Many fibroblasts were seen in a subintimal position but only few in the lining layer, not in sufficient numbers to account for the type-B category of synoviocyte. Staining with a new MoAb, 67, was found to precisely delineate the lining layer. This MoAb was previously seen to react with dendritic reticulum cells (DRC) of germinal centres, cells involved in B lymphocyte activation. However, other MoAb which react with germinal centre DRC did not label the synovial lining layer. Several MoAb revealed features of the vasculature not previously recognized. In rheumatoid samples, MoAb10 labelled small capillaries near the synovial surface and larger vessels deeper in the intima were labelled with a second MoAb, SM phi. This dichotomy of staining was not so apparent in synovium from control osteoarthritis and trauma (OA/T) samples. In addition, the Thy 1 epitope, identified previously on a variety of human cells, was strongly expressed on all vascular endothelium. Finally a new vessel or duct like structure was identified in OA/T samples, located subintimally. These ducts contained keratin, detected with MoAb LE61 and may be the normal counterpart for the rare malignancy, biphasic synovial sarcoma. | |
| 7391173 | Determination of uric acid in serum using isotachophoresis. | 1980 Jun 13 | An operational system is described for the isotachophoretic determination of uric acid in serum, making use of column coupling. The method has been compared with a standard enzymatic procedure. With the present technique small amounts of serum (ca. 3 microliter) can be applied without any pretreatment. Urate recovery was 99.0-100.5%. Under the non-physiological measuring conditions used, 12-28% of control serum uric acid was bound to macromolecules of molecular weight exceeding 25,000. The day-to-day variations of the isotachophoretic procedure were smaller than those of the enzymatic method, whereas standard deviations were comparable. The isotachophoretic procedure is less influenced by certain metabolites. | |
| 795797 | Problems with beaded fluorescence pattern in FTA-ABS test. | 1976 Sep | The significance of false-positive FTA-ABS fluorescence in connective tissue diseases and other clinical conditions was evaluated by studying the serum from several groups of patients. In 12% of 67 patients without syphilis, serum with an antinuclear antibody (ANA) titer of 1:32 or greater gave low intensity FTA-ABS test fluorescence. In 20% of 150, patients (2.7% with a history of syphilis), serum with rheumatoid factor (RF) titers of 1:640 or greater demonstrated some reactivity. Only 1.3% of 75 donors of normal blood showed low-grade FTA-ABS fluorescence. In 385 patients with diagnostic problems, 2.1% of the serum demonstrated the beaded pattern. Patterns varied, depending on the treponemal antigen preparation and the duration of serum storage. Also, multiple specimens from the same patient produced different patterns. Furthermore, the beaded pattern could be demonstrated in patients with a history of syphilis, with other medical disorders, and in apparently normal persons. | |
| 6971729 | Further studies on glucametacin in rheumatoid arthritis and in other chronic types of rheu | 1981 | Twenty-three patients with rheumatoid arthritis and 9 patients with other forms of rheumatic diseases were treated for 20 days with 420 mg glucametacin per day, given as three 140 mg capsules. The treatment produced anti-inflammatory effects which were rated as good in about half the cases, with improvement of the majority of the clinical parameters studied. There were mild digestive side-effects. One patient with gallstones developed biliary colic, but the relationship of this to glucametacin treatment was not clear. The results obtained in the 32 patients treated with 140 mg glucametacin capsules were very similar to those which the same authors had observed in a very extensive case series of patients with rheumatic diseases treated with the same daily dose, but given as 70 mg capsules. It is suggested that the new preparation, which halves the number of capsules taken each day, is to be preferred to the smaller dose capsules. | |
| 1096702 | The immunofluorescent "band" test in mixed connective tissue disease. | 1975 Jul | Skin biopsy specimens from normal subjects and patients with mixed connective tissue disease, systemic lupus erythematosus, and rheumatoid arthritis were examined for the presence of a "band" of immunoglobulins and complement at the dermal-epidermal junction, using immunofluorescent techniques. A positive immunofluorescent band test was found in the clinically uninvolved skin in three of six patients with mixed connective tissue disease, five of six patients with systemic lupus erythematosus, and none of the patients with rheumatoid arthritis or normal subjects. Although a positive immunofluorescent band test in uninvolved skin has been considered to be fairly specific for the diagnosis of systemic lupus erythematosus, our results suggest that this test cannot be used to distinguish mixed connective tissue disease from systemic lupus erythematosus. | |
| 942278 | Experimental arthritis of rabbits caused by intra-articular injection of autologous Fab2 p | 1976 Apr | Intra-articularly injected autologous Fab2 produced from IgG by homologous cathepsin D induces in animals not given prior immunization acute synovitis after 1 and 3 injections, acute synovitis after 6 injections, and chronic synovitis after 12 injections. Histologically, the chronic synovitis is similar to synovitis in rheumatoid arthritis (RA). In the joint, cathepsin D Fab2 appears to act as a fairly strong antigen. Evidence for this is provided by the infiltration of large numbers of polymorphonuclear leucocytes, the marked phagocytic activity of the exudate leucocytes and tissue phagocytes, and the stimulation of the synthesis of specific antibodies (homoreactants) in the synovial plasma cells. The immediate action of injected Fab2 suggests that it forms biologically active immune complexes with homoreactants already present. These complexes are phagocytosed, the homoreactants being demonstrable immunohistochemically in inclusions of the exudate and tissue phagocytes. In addition, the local synthesis of antigammaglobulins of rheumatoid factor type is also induced. These react with heat-aggregated homologous as well as human IgG and are likewise found in inclusions in the exudate and tissue phagocytes. In the serum of the animals the titre of rheumatoid factor-like antigammaglobulins increases to an extent depending on the number of injections given. These histochemical and serological findings show striking parallels with the findings in human RA. | |
| 6332907 | Antibodies to native and denatured type II collagen in children with rheumatic diseases. | 1984 Aug | Sera of 153 children with rheumatic diseases were assayed by an enzyme-linked immunosorbent assay (ELISA) for the presence of antibodies to native (n) and to denatured (d) type II collagen (IIC). Among the study population, antibodies to nIIC were detected in 47% with juvenile rheumatoid arthritis (JRA), 21% with spondyloarthropathies, 37% with other rheumatic diseases, 70% with adult onset rheumatoid arthritis (RA), and in less than 1% of nonrheumatic disease control groups. Antibodies to dIIC were detected in 42% of children with JRA, 41% with spondyloarthropathies, 37% of children with other rheumatic diseases, 67% with adult onset RA, and in less than 6% of nonrheumatic disease control groups. These results indicate that, when compared to nonrheumatic disease control groups, antibodies to both nIIC and dIIC occur significantly more frequently in children with a variety of rheumatic diseases. | |
| 48775 | Rubella-virus infection in juvenile rheumatoid arthritis. | 1975 May 24 | Antibody activity against mumps, measles, polio, and rubella viruses was determined in patients with juvenile rheumatoid arthritis (J.R.A.), rubella-vaccine associated arthritis, adult rheumatoid arthritis, other chronic systemic disorders (e.g., systemic lupus and dermatomyositis), and in a matched population of normal, non-rheumatoid (control) children. The antibody levels against mumps, measles, and poliovirus were similar in all patients. Rubella-antibody levels in rheumatoid arthritis and other systemic disorders were similar to those observed in controls. The mean rubella-antibody levels in rubella-vaccine arthritis were 4 times higher than in controls. The IgM and IgG rubella-antibody levels in J.R.A. were found to be 4-6 times higher when compared to titres observed in the controls. Highest antibody levels were seen in younger children with J.R.A. Detection of rubella-virus antigen was attempted by immunofluorescence in the sediment smears of synovial fluid of patients with J.R.A., adult rheumatoid arthritis, and other non-rheumatoid joint diseases. Specific staining for rubella virus antigen was observed in the synovial fluid of 33 percent of patients with J.R.A. No antigen was detected in the synovial fluid from other patients. These observations suggest a possible role of rubella-virus infection in J.R.A. |